Jacobs Levy Equity Management
STOK icon

Jacobs Levy Equity Management’s Stoke Therapeutics STOK Stock Holding History

Jacobs Levy Equity Management’s Portfolio STOK Stock Details STOK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-12,878
Closed -$409K – 1061
2025
Q4 		$409K Sell
12,878
-2,207
-15% -$66.3K ﹤0.01% 831
2025
Q3 		$354K Sell
15,085
-108,397
-88% -$1.86M ﹤0.01% 858
2025
Q2 		$1.4M Sell
123,482
-233,766
-65% -$2.22M 0.01% 691
2025
Q1 		$2.38M Buy
+357,248
New +$3.33M 0.01% 619
2024
Q3 		– Sell
-46,059
Closed -$622K – 1042
2024
Q2 		$622K Sell
46,059
-1,853
-4% -$25K ﹤0.01% 813
2024
Q1 		$647K Sell
47,912
-120,116
-71% -$728K ﹤0.01% 785
2023
Q4 		$884K Sell
168,028
-49,577
-23% -$212K ﹤0.01% 744
2023
Q3 		$857K Buy
+217,605
New +$1.43M 0.01% 700
2022
Q1 		– Sell
-22,480
Closed -$539K – 1084
2021
Q4 		$539K Buy
+22,480
New +$536K ﹤0.01% 824
2020
Q4 		– Sell
-6,683
Closed -$224K – 1094
2020
Q3 		$224K Buy
+6,683
New +$191K ﹤0.01% 942

Other funds holding STOK

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Jacobs Levy Equity Management's STOK Position: Q1 2026 in Review

Jacobs Levy Equity Management sold out of Stoke Therapeutics (STOK) in Q1 2026, closing a stake of 12,878 shares — an estimated $409K sold.

Jacobs Levy Equity Management first reported a position in STOK in Q3 2020 and held it in 10 quarters. The position peaked at $2.38M in Q1 2025. 196 funds tracked by Wall St. Rank hold STOK as of Q1 2026.

  • Jacobs Levy Equity Management reported no remaining Stoke Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Jacobs Levy Equity Management sold 12,878 Stoke Therapeutics shares in Q1 2026, an estimated $409K.
  • Jacobs Levy Equity Management first reported a position in Stoke Therapeutics in Q3 2020 and held it in 10 quarters.
  • Jacobs Levy Equity Management's Stoke Therapeutics position peaked at $2.38M in Q1 2025.
  • 196 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q1 2026.

Based on Jacobs Levy Equity Management's 13F filing for Q1 2026, filed 15 May 2026.